Outcome of 33rd Annual General Meeting held on 21.08.2026.

J-} Oxygenta N VIRUPAKSHA Date: 21.08.2026 The Manager BSE Limited P.J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Sub: Outcome of Annual General Meeting held on 21%* August, 2026. Unit: Oxygenta Pharmaceutical Limited (BSE Scrip Code: 524636) With reference to the subject cited above, this is to inform the Exchange that the 33" Annual General Meeting of Oxygenta Pharmaceutical Limited was held on Friday, 21% day of August, 2026 at 10:30 a.m. through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). In this regard, please find enclosed the following: - (1) Summary of proceedings as required under Regulation 30, Part-A of Schedule -III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure — I (2) Voting Results of the business transacted at the AGM held on Friday, 21 August, 2026 as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure — IL. (3) Report of Scrutinizer pursuant to Sec. 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as Annexure - III. The Meeting concluded at 11:15 AM (Including the voting period). This is for the kind information and records of the Exchange, please. Thanking you. Yours faithfully, For Oxygenta Pharmaccutical Limited Kumkum Bajaj Company Secretary & Compliance Officer M.No.: ACS76548 OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An 180 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company) Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com Phone: 040-23073417, CIN: L24110TG1990PLC012038 &) Oxygenta VIRUPAKSHA Date: 21.08.2026 The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Sub: Summary of Proceedings of Annual General Meeting held on Friday, 21% August, 2026 as required under Regulation 30, PART - A of the schedule 111 of the SEBI (Listing Obligations and Disclosure Requirements), 2015. Unit: Oxygenta Pharmaceutical Limited (BSE Scrip Code: 524636) Summary of proceedings of the Annual General Meeting: The 33 Annual General Meeting (AGM) of the Members of Oxygenta Pharmaceutical Limited (‘the Company’) was held on Friday, 21¢ August, 2026 at 10:30 AM (IST) through Video conference /Other audio-visual means, in compliance with the General Circulars issued by the Ministry of Corporate Affairs (MCA) and circulars issued by the Securities and Exchange Board of India (SEBI) in this regard and as per the applicable provisions of the Companies Act, 2013 and the Rules made thereunder. Directors and KMP present (all present through VC): S. No Name Designation 1. Mr. Chandra Mouliswar Reddy ‘Whole-time Director Gangavaram 2. | Mr. Balasubba Reddy Mamilla ‘Whole-time Director 3. | Mrs. Vedavathi Gangavaram Non- Executive Director 4. | Dr. Veera Reddy Arava Independent Director 5. | Mr. Sidda Reddy Kanuparthi Independent Director 6. | Mrs. Sharvari Swapnil Shinde Independent Director 7. | Mr. Janardhana Reddy Yeddula Independent Director 8. | Mr. Amireddy Venkatesu Reddy Whole-time Director 9. | Mr. Prasad Reddy Battinapatla Chief Financial Officer (CFO) 10{ Ms. Kumkum Bajaj Company Secretary and Compliance Officer Other Invitees in attendance (all present through VC): S.No | Name Designation 1.| M/s. A.M. Reddy & D.R. Reddy Statutory Auditors 2.| M/s. Aakanksha Dubey & Co. Secretarial Auditor and Scrutinizer 3.| M/s. Suryanarayana & Associates Internal Auditors 4.| M/s. PCR & Associates Cost Auditors OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An IS0 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certiied Company) Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com Phone: 040-23073417, CIN: L24110TG1990PLC012038 ¢y Oxygenta VIRUPAKSHA Quorum of the meeting: A total of 75 members attended the meeting through VC. The meeting commenced at 10:30 A.M. (IST) and concluded at 11:15 A.M. (IST) (including time allowed for e- voting at AGM). Proceedings of the Meeting: The Company Secretary extended a warm welcome to all members, auditors and other invitees who joined the meeting through VC. The Company Secretary then introduced the Directors and Key Managerial Personnels (KMP) of the Company to the members. All the Directors and KMPs of the Company attended the meeting. The team then provided general instructions to members regarding participation in the meeting and to cast their votes through insta-poll and confirmed that the Company had taken all feasible efforts to enable members to participate through VC and vote on the items being considered for the meeting. Since the Company does not have a regular Chairman of the Board the Company Secretary requested the Directors present at the Meeting to elect one of themselves to be the Chairman of the Meeting. Accordingly, with the consent of all the Directors present in the meeting Mr. Chandra Mouliswar Reddy Gangavaram, Whole-time Director of the Company was appointed as the Chairman of the meeting. After declaring that the requisite quorum was present, the meeting was called to order. Thereafter, with the permission of the Chair, Notice of AGM and Board’s Report was taken as read. The Company Secretary then read out the following items of business, as per the Notice of AGM: Sr. Description of Resolutions Type of No. resolution 1. | To receive, consider and adopt the Audited Standalone Financial Statements of | Ordinary the Company for the financial year ended 31 March 2026, together with the Reports of the Board of Directors and Auditor’s thereon. 2. | To appoint a director in place of Mr. Balasubba Reddy Mamilla | Ordinary (DIN: 01998852), who retires by rotation and being eligible, offers himself for re-appointment. 3. | Toappoint Mr. Amireddy Venkatesu Reddy (DIN: 11087687) as a Director and | Special ‘Whole-time Director of the Company. 4. | To appoint Mr. Janardhana Reddy Yeddula (DIN 03207357) as an Independent | Special Director of the Company. 5. | To approve Material Related Party Transactions (Sale and Purchase) of the | Ordinary Company with M/s. Virupaksha Organics Limited, Holding Company. OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An 1SO 9001:2015, ISO 14001:2018 and 1SO 45001:2015 Certified Company) Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com Phone: 040-23073417, CIN: L24110TG1990PLC012038 N Oxygenta To approve Material Related Party Transactions (Loan and Guarantee) of the | Ordinary VIRUPAKSHA Company with M/s. Virupaksha Organics Limited, Holding Company. 7. | Ratification of payment of Remuneration to the Cost Auditor for the Financial | Ordinary Year 2026-27. Since, all the Resolutions had been already put to vote through remote e-voting, there was no proposing and seconding of the Resolutions and no voting by show of hands. Members were then provided with a facility to ask questions or express their views through VC. The members acknowledged the efforts of the Board, Management, and Compliance teams in ensuring proper compliance. They briefly asked questions on the financials and future outlook of the Company. Satisfactory responses were duly provided by Mr. Prasad Reddy Battinapatla, Chief Fi [Showing first 8,000 characters — download PDF for full document]